Publications by authors named "Vlad Bogin"
In a randomized double-blinded clinical trial of patients with ST segment elevation myocardial infarction (STEMI), goflikicept, an interleukin-1 blocker, significantly reduced systemic inflammation, measured as the area under the curve (AUC) for high-sensitivity C reactive protein at 14 days. We report secondary analyses of biomarkers at 28 days, and cardiac function and clinical end points at 1 year. Patients received a single administration of goflikicept 80 mg (n = 34), goflikicept 160 mg (n = 34), or placebo (n = 34).
View Article and Find Full Text PDFArticle Synopsis
- Opioid withdrawal symptoms (OWS) can lead to increased opioid use and serious health risks, influenced by hyperactivity in the sympathetic nervous system when opioid levels drop.
- This study tested whether inhaling xenon gas, known to inhibit sympathetic activity, could reduce withdrawal symptoms in morphine-dependent mice after they were given naltrexone.
- Results showed that mice exposed to xenon exhibited significantly fewer jumping behaviors associated with withdrawal, suggesting that xenon could potentially help reduce OWS in humans, leading to better treatment outcomes for opioid use disorder.